Clinical Trials Logo

Clinical Trial Summary

An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05698459
Study type Interventional
Source Binhui Biopharmaceutical Co., Ltd.
Contact chuansheng zheng, MD
Phone 13329702158
Email 13329702158@163.com
Status Recruiting
Phase Phase 1
Start date May 5, 2023
Completion date January 2025

See also
  Status Clinical Trial Phase
Completed NCT01754987 - A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Phase 1/Phase 2
Recruiting NCT03146637 - Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer Phase 2
Withdrawn NCT03484962 - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer Phase 2
Recruiting NCT05603039 - A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04906434 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor Phase 1
Recruiting NCT04163237 - Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer Phase 3
Recruiting NCT02862613 - Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer Phase 1/Phase 2
Recruiting NCT02873442 - Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer Phase 1/Phase 2
Recruiting NCT03474822 - Plasmodium Immunotherapy for Breast and Liver Cancers Phase 1/Phase 2